Natural history of NGLY1 deficiency: motor function & clinical features
Open Access
- 11 May 2026
- journal article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 35 (8)
Abstract
N-glycanase 1 (NGLY1) Deficiency is an ultra-rare neurodevelopmental disorder caused by biallelic loss-of-function mutations in the NGLY1 gene, leading to severe impairments in neurocognitive and motor function abilities in the affected patient population. Its core clinical features include global developmental delay, hyperkinetic movement disorders, elevation of liver transaminases, (hypo)alacrima, and progressive sensorimotor neuropathy. Due to the range of phenotypes and severity within the confirmed patient population, ongoing characterization of the disease is critical. A prospective natural history study (NHS) was conducted to further elucidate disease phenotypes and examine any changes in neurocognitive or motor function over a one-year period. Fifteen participants, representing roughly 10% of the total identified patient population, were enrolled to complete three onsite visits. Participants in this study exhibited phenotypes previously reported, including core disease phenotypes, hypotonia, scoliosis, musculoskeletal abnormalities, abnormal electroencephalogram (EEG) results, and visual and genitourinary abnormalities. Results from validated neurocognitive and motor function assessments revealed profound global developmental delays in all participants, including communication, gross and fine motor function, and cognitive domains. Age-equivalent scores identified a widening developmental gap between participants and neurotypical peers over time, indicating delayed milestone achievement and/or regression. Although fluctuations were observed, measurements for individual participants were mostly stable over the course of the NHS. Liver transaminase and biomarker N-acetylglucosamine-asparagine (GlcNAc-Asn; GNA) levels were elevated in all participants. Results build on previous studies and inform the selection of potential endpoints for emerging interventional clinical trials, including laboratory values, neurocognitive and motor function assessments, and caregiver reported outcomes.Keywords
Funding Information
- Grace Science Foundation
This publication has 23 references indexed in Scilit:
- Orthopaedic phenotyping of NGLY1 deficiency using an international, family-led disease registryOrphanet Journal of Rare Diseases, 2019
- Unexplained death in patients with NGLY1 mutations may be explained by adrenal insufficiencyPhysiological Reports, 2019
- Diagnosis and genetics of alacrimaClinical Genetics, 2018
- The Gross Motor Function Measure (GMFM)Journal of Physiotherapy, 2017
- The cytoplasmic peptide:N-glycanase (NGLY1) — Structure, expression and cellular functionsGene, 2016
- A congenital disorder of deglycosylation: Biochemical characterization ofN-glycanase 1 deficiency in patient fibroblastsGlycobiology, 2015
- NGLY1 mutation causes neuromotor impairment, intellectual disability, and neuropathyEuropean Journal of Medical Genetics, 2015
- Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum–associated degradation pathwayGenetics in Medicine, 2014
- Clinical application of exome sequencing in undiagnosed genetic conditionsJournal of Medical Genetics, 2012
- The Gross Motor Function Classification System – Expanded and RevisedDevelopmental Medicine & Child Neurology, 2008